Positive News Coverage Somewhat Unlikely to Affect CareFusion (CFN) Stock Price
Headlines about CareFusion (NYSE:CFN) have trended positive on Monday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CareFusion earned a daily sentiment score of 0.26 on Accern’s scale. Accern also gave media coverage about the healthcare company an impact score of 47.9342469896499 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of CareFusion (CFN) remained flat at $$59.94 during midday trading on Monday. The firm has a market cap of $12,240.00 and a PE ratio of 25.51.
CareFusion Company Profile
CareFusion Corporation is a global medical technology company. The Company operates in two business segments: Medical Systems and Procedural Solutions. The Company’s primary product brands include: Alaris intravenous (IV) infusion systems; Pyxis and Rowa automated medication dispensing and supply management systems; AVEA, Vela and LTV Series respiratory ventilators; ChloraPrep skin antiseptic products; MaxGuard, MaxPlus, MaxZero, SmartSite and Texium needle-free IV infusion valves, administration sets and accessories; V.
Receive News & Ratings for CareFusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareFusion and related companies with MarketBeat.com's FREE daily email newsletter.